CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 119 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $76,677 | +197.8% | 2,578,199 | +80.4% | 0.01% | +175.0% |
| Q2 2023 | $25,750 | +3731.8% | 1,428,910 | +3319.8% | 0.00% | – |
| Q1 2023 | $672 | -29.3% | 41,783 | -19.5% | 0.00% | – |
| Q4 2022 | $951 | -99.9% | 51,931 | -15.7% | 0.00% | – |
| Q3 2022 | $1,212,000 | +19.4% | 61,635 | +13.3% | 0.00% | – |
| Q2 2022 | $1,015,000 | +23.0% | 54,407 | +44.8% | 0.00% | – |
| Q1 2022 | $825,000 | -62.2% | 37,583 | -51.1% | 0.00% | – |
| Q4 2021 | $2,183,000 | +56.7% | 76,822 | +16.1% | 0.00% | – |
| Q3 2021 | $1,393,000 | +12.1% | 66,163 | +0.4% | 0.00% | – |
| Q2 2021 | $1,243,000 | +66.4% | 65,925 | +34.9% | 0.00% | – |
| Q1 2021 | $747,000 | -34.6% | 48,865 | -39.6% | 0.00% | – |
| Q4 2020 | $1,142,000 | -15.3% | 80,902 | -6.0% | 0.00% | – |
| Q3 2020 | $1,349,000 | -10.5% | 86,068 | 0.0% | 0.00% | – |
| Q2 2020 | $1,508,000 | +260.8% | 86,068 | +203.0% | 0.00% | – |
| Q1 2020 | $418,000 | -53.9% | 28,408 | -21.3% | 0.00% | – |
| Q4 2019 | $906,000 | +15.3% | 36,108 | -30.9% | 0.00% | – |
| Q3 2019 | $786,000 | -93.6% | 52,283 | -89.3% | 0.00% | -100.0% |
| Q2 2019 | $12,198,000 | +10.2% | 487,916 | +0.4% | 0.00% | 0.0% |
| Q1 2019 | $11,064,000 | -15.0% | 486,130 | +12.0% | 0.00% | 0.0% |
| Q4 2018 | $13,016,000 | +4.7% | 433,996 | +0.0% | 0.00% | 0.0% |
| Q3 2018 | $12,431,000 | – | 433,905 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |